CN112105320A - 治疗近视进展 - Google Patents

治疗近视进展 Download PDF

Info

Publication number
CN112105320A
CN112105320A CN201980014086.4A CN201980014086A CN112105320A CN 112105320 A CN112105320 A CN 112105320A CN 201980014086 A CN201980014086 A CN 201980014086A CN 112105320 A CN112105320 A CN 112105320A
Authority
CN
China
Prior art keywords
copper
composition
eye
agent
ophthalmic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980014086.4A
Other languages
English (en)
Chinese (zh)
Inventor
R·M·伯尔
B·K·阿姆巴提
S·A·莫洛希亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Publication of CN112105320A publication Critical patent/CN112105320A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CN201980014086.4A 2018-01-05 2019-01-07 治疗近视进展 Pending CN112105320A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862614230P 2018-01-05 2018-01-05
US62/614,230 2018-01-05
PCT/US2019/012501 WO2019136358A1 (en) 2018-01-05 2019-01-07 Treatment of myopic progression

Publications (1)

Publication Number Publication Date
CN112105320A true CN112105320A (zh) 2020-12-18

Family

ID=67143996

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980014086.4A Pending CN112105320A (zh) 2018-01-05 2019-01-07 治疗近视进展

Country Status (8)

Country Link
US (2) US11524032B2 (enExample)
EP (1) EP3735209A4 (enExample)
JP (3) JP7324208B2 (enExample)
KR (2) KR102831250B1 (enExample)
CN (1) CN112105320A (enExample)
AU (2) AU2019205774B2 (enExample)
CA (1) CA3087622A1 (enExample)
WO (1) WO2019136358A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114364355A (zh) * 2019-07-11 2022-04-15 犹他大学研究基金会 多剂眼科制剂和治疗方法
CN115282349A (zh) * 2022-07-05 2022-11-04 复旦大学附属眼耳鼻喉科医院 一种有利于改善孟加拉玫瑰红-绿光角膜胶原交联技术中cct降低的角膜交联试剂
CN115386105A (zh) * 2022-08-26 2022-11-25 昆明理工大学 多重酶活性纳米酶荧光水凝胶的制备方法及应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3426262B1 (en) * 2016-03-08 2023-08-23 University of Utah Research Foundation Cross-linking agents and associated methods
WO2019136358A1 (en) 2018-01-05 2019-07-11 Iveena Delivery Systems, Inc. Treatment of myopic progression
TW202245810A (zh) * 2021-02-01 2022-12-01 美商艾維娜傳送系統公司 散光之治療
TW202302121A (zh) * 2021-02-11 2023-01-16 猶他大學研究基金會 近視之治療

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3416530A (en) * 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
EP1159941A2 (en) * 1991-10-15 2001-12-05 Ista Pharmaceuticals, Inc. Formulations for use in enzyme-orthokeratology
CN1518981A (zh) * 2003-07-23 2004-08-11 复旦大学附属眼耳鼻喉科医院 一种治疗近视的外用滴眼制剂
CN1753683A (zh) * 2002-12-20 2006-03-29 视可舒研究公司 预防和治疗不良眼部病症的眼用制剂
CN1901882A (zh) * 2003-12-19 2007-01-24 奥西奥公司 眼病的治疗
EP3103446A2 (en) * 2013-12-17 2016-12-14 Zakharov, Ivan Dmitrievich Pharmaceutical preparation for preventing and treating progressive myopia
CN106413644A (zh) * 2014-04-09 2017-02-15 莱比锡大学 用于巩膜的医学治疗的装置
WO2017155580A1 (en) * 2016-03-08 2017-09-14 University Of Utah Research Foundation Cross-linking agents and associated methods

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075105A (en) 1989-09-27 1991-12-24 Avetisov Eduard S Composition for treatment of progressive myopia
CN1047523C (zh) 1993-11-23 1999-12-22 华中理工大学 一种防治近视的滴眼液
BR9908692A (pt) * 1998-03-09 2001-12-04 Ista Pharmaceuticals Inc Uso de agentes de enrijecimento corneal emortocerotologia enzimática
US6231889B1 (en) * 1998-09-21 2001-05-15 Chronorx, Llc Unit dosage forms for the treatment of herpes simplex
WO2002083873A2 (en) * 2001-04-13 2002-10-24 Incyte Genomics, Inc. Enzymes
CA2587391A1 (en) 2004-11-16 2006-05-26 Nu-Tein Co., Inc. Compositions useful to treat ocular neovascular diseases and macular degeneration
US20060276777A1 (en) * 2005-04-08 2006-12-07 Coroneo Minas T Corneal shaping
US20080014247A1 (en) 2006-06-30 2008-01-17 Nucryst Pharmaceuticals Metal-containing formulations and methods of use
EP2999471B1 (en) * 2013-05-19 2020-12-16 Avedro, Inc. Systems, methods, and compositions for cross-linking
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
MX2017012999A (es) * 2015-04-09 2018-05-22 Laboratori Baldacci Spa Acido pirrolidona carboxilico (pca) para uso oftalmico.
US10010502B2 (en) 2015-05-19 2018-07-03 Amorphex Therapeutics Llc Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
AU2018371787A1 (en) 2017-11-21 2020-11-05 Sydnexis, Inc. Ophthalmic composition and delivery device thereof
WO2019136358A1 (en) * 2018-01-05 2019-07-11 Iveena Delivery Systems, Inc. Treatment of myopic progression
JP2022541152A (ja) * 2019-07-11 2022-09-22 ユニバーシティー オブ ユタ リサーチ ファウンデーション 多形態眼球製剤および治療法
TW202245810A (zh) * 2021-02-01 2022-12-01 美商艾維娜傳送系統公司 散光之治療
TW202302121A (zh) * 2021-02-11 2023-01-16 猶他大學研究基金會 近視之治療

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3416530A (en) * 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
EP1159941A2 (en) * 1991-10-15 2001-12-05 Ista Pharmaceuticals, Inc. Formulations for use in enzyme-orthokeratology
CN1753683A (zh) * 2002-12-20 2006-03-29 视可舒研究公司 预防和治疗不良眼部病症的眼用制剂
CN1518981A (zh) * 2003-07-23 2004-08-11 复旦大学附属眼耳鼻喉科医院 一种治疗近视的外用滴眼制剂
CN1901882A (zh) * 2003-12-19 2007-01-24 奥西奥公司 眼病的治疗
EP3103446A2 (en) * 2013-12-17 2016-12-14 Zakharov, Ivan Dmitrievich Pharmaceutical preparation for preventing and treating progressive myopia
CN106413644A (zh) * 2014-04-09 2017-02-15 莱比锡大学 用于巩膜的医学治疗的装置
WO2017155580A1 (en) * 2016-03-08 2017-09-14 University Of Utah Research Foundation Cross-linking agents and associated methods

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114364355A (zh) * 2019-07-11 2022-04-15 犹他大学研究基金会 多剂眼科制剂和治疗方法
CN115282349A (zh) * 2022-07-05 2022-11-04 复旦大学附属眼耳鼻喉科医院 一种有利于改善孟加拉玫瑰红-绿光角膜胶原交联技术中cct降低的角膜交联试剂
CN115386105A (zh) * 2022-08-26 2022-11-25 昆明理工大学 多重酶活性纳米酶荧光水凝胶的制备方法及应用
CN115386105B (zh) * 2022-08-26 2024-03-22 昆明理工大学 多重酶活性纳米酶荧光水凝胶的制备方法及应用

Also Published As

Publication number Publication date
KR102831250B1 (ko) 2025-07-08
EP3735209A1 (en) 2020-11-11
KR20250109788A (ko) 2025-07-17
AU2024278182A1 (en) 2025-01-02
JP7655988B2 (ja) 2025-04-02
US20230256012A1 (en) 2023-08-17
KR20200118426A (ko) 2020-10-15
AU2019205774B2 (en) 2025-01-02
US11524032B2 (en) 2022-12-13
CA3087622A1 (en) 2019-07-11
JP2021509902A (ja) 2021-04-08
JP2025111434A (ja) 2025-07-30
EP3735209A4 (en) 2021-09-08
US20210060059A1 (en) 2021-03-04
JP2023153905A (ja) 2023-10-18
WO2019136358A1 (en) 2019-07-11
AU2019205774A1 (en) 2020-08-06
JP7324208B2 (ja) 2023-08-09

Similar Documents

Publication Publication Date Title
US20230256012A1 (en) Treatment of myopic progression
AU2023202236B2 (en) Cross-linking agents and associated methods
CN115279378A (zh) 包含d2o的眼用组合物
AU2020311441B2 (en) Multi-agent ocular formulations and treatment methods
US20180221407A1 (en) Ophthalmic compositions for therapeutic and prophylactic uses
KR20240021734A (ko) 근시의 치료
HK40107891A (en) Cross-linking agents and associated methods

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination